HF
BIOTW

HRT Financial’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

HRT Financial’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-66,828
Closed -$4K – 3570
2022
Q4 		$4K Hold
66,828
– – ﹤0.01% 2299
2022
Q3 		$4K Hold
66,828
– – ﹤0.01% 2622
2022
Q2 		$2K Buy
66,828
+44,877
+204% +$9.27K ﹤0.01% 2812
2022
Q1 		$5K Buy
21,951
+2,600
+13% +$829 ﹤0.01% 2960
2021
Q4 		$12K Buy
+19,351
New +$13.4K ﹤0.01% 3010

HRT Financial's BIOTW Position: Q1 2023 in Review

HRT Financial sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 66,828 shares — an estimated $4K sold.

HRT Financial first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $12K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

  • HRT Financial reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
  • HRT Financial sold 66,828 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $4K.
  • HRT Financial first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
  • HRT Financial's Biotech Acquisition Company Warrant position peaked at $12K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.